Rituximab for late onset myasthenia gravis: Evidence mounting but deliberations continue
- PMID: 32530500
- DOI: 10.1002/mus.26998
Rituximab for late onset myasthenia gravis: Evidence mounting but deliberations continue
Comment on
-
Rituximab in late-onset myasthenia gravis is safe and effective.Muscle Nerve. 2020 Sep;62(3):377-380. doi: 10.1002/mus.26876. Epub 2020 Apr 15. Muscle Nerve. 2020. PMID: 32239711
References
REFERENCES
-
- Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150-151.
-
- Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010;17:1445-1450.
-
- Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141-149.
-
- Cortes-Vicente E, Alvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94:e1171-e1180.
-
- Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology. 2003;60:1024-1026.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical